Publications by authors named "Shu-Na Yao"
Article Synopsis
- Recent studies indicate a rising number of anticancer drugs approved for patients with blood-related cancers, but there's limited data on the risk of hepatitis B virus reactivation (HBV-R) in these patients.
- In a study of 845 patients, 30.5% were found at risk for HBV-R, with a low overall incidence of 2.1% in those with past HBV infections.
- The findings suggest that most cases of HBV-R are preventable and manageable, indicating that patients with HBV infection can still receive novel anticancer treatments without significant risk.
Advanced esophageal squamous cell carcinoma (ESCC) is a lethal disease with poor response to conventional chemotherapy. Immunotherapy showed better activity than chemotherapy in late-line treatment. However, the rate and duration of response are far from satisfactory.
View Article and Find Full Text PDFArticle Synopsis
- Primary mediastinal large B-cell lymphoma (PMBCL) is a rare type of lymphoma that usually responds well to standard treatment but poses challenges for relapsed cases unable to undergo stem cell transplantation.
- A patient with refractory PMBCL, who did not respond to salvage chemotherapy, was treated with a combination of nivolumab (an immunotherapy) and radiotherapy.
- Remarkably, the patient achieved complete remission, experienced only mild side effects, and has remained relapse-free for 2 years following treatment.
Purpose: Anlotinib, a newly developed oral small-molecule receptor tyrosine kinase inhibitor (TKI), has been shown to have encouraging activity against sarcoma. The purpose of this study was to retrospectively evaluate the safety and clinical efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in advanced/metastatic soft tissue sarcoma (STS) patients in a real-world setting in China.
Patients And Methods: We retrospectively collected the medical data of thirty-two patients with advanced/metastatic STS who received chemotherapy combined with anlotinib plus anlotinib maintenance therapy.
Purpose: One third of patients with diffuse large B-cell lymphoma (DLBCL) succumb to the disease partly due to rituximab resistance. Rituximab-induced calcium flux is an important inducer of apoptotic cell death, and we investigated the potential role of calcium channels in rituximab resistance.
Experimental Design: The distinctive expression of calcium channel members was compared between patients sensitive and resistant to rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone (RCHOP) regimen.
Background: In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable. The current clinical study was conducted to retrospectively compare the efficacy and safety of first-line paclitaxel/S-1(PS) and paclitaxel/cisplatin(TP) regimens in advanced ESCC.
Results: The overall response rate of PS was slightly, but not significantly, higher (25 patients, 46%) than that of TP (23 patients, 39%, P = 0.
Objective: More effective regimens for advanced esophageal squamous cell carcinoma (ESCC) are urgently needed. Therefore, a retrospective study concerning the efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin (nab-TP) versus solvent-based paclitaxel plus cisplatin (sb-TP) as a first-line therapy was conducted in Chinese patients with advanced ESCC.
Methods: From June 2009 to June 2015, 32 patients were treated with nab-paclitaxel (125 mg/m) on the first and eighth days (30 minutes infusion) and cisplatin (75 mg/m) on the second day every 21 days (nab-TP arm).
Article Synopsis
- There is no standard treatment for extranodal natural killer (NK)/T-cell lymphoma (ENKTCL), prompting researchers to evaluate a new combination therapy known as the GOLD regimen.
- The GOLD regimen, involving gemcitabine, oxaliplatin, L-asparaginase, and dexamethasone, showed a 91% overall response rate in a study of 55 patients, with significant progression-free and overall survival rates.
- Results indicated that the GOLD regimen is both effective and safe, with no severe complications or chemotherapy-related mortality reported, making it a promising option for treating newly-diagnosed ENKTCL.
[Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
August 2013
Objective: To evaluate the inhibitory effect and its mechanism of celecoxib combined with capecitabine on the growth of implanted H22 hepatoma in mice.
Methods: Tumor model was established by hypodermical injection of H22 cells in BALB/c nude mice. Forty mice were equally randomly divided into 4 groups: control group, celecoxib group (receiving 100 mg/kg celecoxib), capecitabine group (receiving 755 mg/kg capecitabine), and combined treatment group (receiving 100 mg/kg of celecoxib and 755 mg/kg of capecitabine).
p63 is highly expressed in some malignant tumors and is associated with tumorigenesis, invasion and metastasis. The aim of our study was to evaluate the clinical significance of p63 in colorectal cancer (CRC). p63 expression was detected by immunohistochemistry in 66 CRC patients.
View Article and Find Full Text PDFThe phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and P53 tumor suppressors are among the most commonly inactivated or mutated genes in human cancers, whose pathways cross-talk and interact in a complementary mode. In order to understand their roles and relationship in diffuse large B-cell lymphoma (DLBCL), we examined their expression and evaluated their prognostic significance in 62 patients with DLBCL treated with standard chemotherapy. Results showed that PTEN protein was lost in 23 (37.
View Article and Find Full Text PDF